KR20170142632A - Composition of functional cosmetics and over the counter drugs for treating and improving acne - Google Patents

Composition of functional cosmetics and over the counter drugs for treating and improving acne Download PDF

Info

Publication number
KR20170142632A
KR20170142632A KR1020160076415A KR20160076415A KR20170142632A KR 20170142632 A KR20170142632 A KR 20170142632A KR 1020160076415 A KR1020160076415 A KR 1020160076415A KR 20160076415 A KR20160076415 A KR 20160076415A KR 20170142632 A KR20170142632 A KR 20170142632A
Authority
KR
South Korea
Prior art keywords
acne
composition
treating
acid
phytosphingosine
Prior art date
Application number
KR1020160076415A
Other languages
Korean (ko)
Other versions
KR101822154B1 (en
Inventor
오한선
정영수
Original Assignee
(주)뷰티화장품
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)뷰티화장품 filed Critical (주)뷰티화장품
Priority to KR1020160076415A priority Critical patent/KR101822154B1/en
Publication of KR20170142632A publication Critical patent/KR20170142632A/en
Application granted granted Critical
Publication of KR101822154B1 publication Critical patent/KR101822154B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • A61K36/03Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • A61K36/04Rhodophycota or rhodophyta (red algae), e.g. Porphyra
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • A61K8/9711Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • A61K8/9717Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/11Preparation or pretreatment of starting material involving culturing conditions, e.g. cultivation in the dark or under defined water stress
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • Y10S514/859

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a composition for treating and alleviating acne, which comprises tranexamic acid (TXA), phytosphingosine-1-phosphate, and a microalgae extract as effective components. By comprising tranexamic acid (TXA), phytosphingosine-1-phosphate, and a microalgae extract as effective components, the composition for treating and alleviating acne according to the present invention is highly effective in treating acne and restoring the skin, and can effectively remove scars and discoloration caused by acne, and thus may be effectively utilized in the production of quasi-drugs or cosmeceutical products relating to acne treatment and alleviation.

Description

여드름 치료 및 개선용 조성물{Composition of functional cosmetics and over the counter drugs for treating and improving acne}TECHNICAL FIELD [0001] The present invention relates to a composition for treating and improving acne,

본 발명은 여드름 치료 및 개선용 조성물에 관한 것이다.The present invention relates to a composition for treating and improving acne.

여드름(acne)은 다양한 연령층에서 나타나는 염증성 피부질환의 하나로서, 유전적 요인, 식생활의 서구화, 호르몬의 불균형 또는 스트레스 등의 원인으로 인해 발병 연령대의 폭이 증가하고 있다.Acne is one of the inflammatory skin diseases that occur in various age groups, and the age range of onset is increasing due to genetic factors, westernization of diet, hormone imbalance or stress.

여드름의 정확한 발병 원인은 밝혀져 있지 않으나, 주로, 피지 분비의 증가, 안드로젠 등과 같이 피지선을 자극하는 호르몬의 분비, 모피지선에서 번식하면서 피지를 분해하여 유리 지방산을 형성하는 프로피오니박테리움 아크네스(Propionibacterium acnes)에 의한 염증 진전, 모낭 내 이상 각화, 유전적 문제 등의 원인이 복합적으로 작용하는 것으로 알려져 있다. 또한, 호기성 피부 상재균은 염증 발생 부위를 더욱 확장시켜 여드름이 악화되는데 영향을 주는 것으로 알려져 있으며, 궁극적으로는 피부 속에서 분비된 피지가 밖으로 빠져나가지 못하고 피부 속에 쌓이게 되어 발병하는 것으로 알려져 있다.Although the precise cause of acne is not known, it is mainly caused by an increase in sebum secretion, secretion of hormones that stimulate sebaceous glands such as androgen, and the production of Propionibacterium acnes acnes ), follicular abnormal keratinization, and genetic problems are known to play a multiplicative role. In addition, it is known that aerobic dermatophytes are known to further exacerbate inflammation and thereby exacerbate acne. Ultimately, it is known that sebum secreted from the skin can not escape from the skin and accumulate in the skin.

최근, 피부 미용에 대한 관심이 증가함에 따라, 여드름의 발생은 심리적 압박, 자신감의 상실, 우울증 등의 다양한 정신적인 질환을 야기할 수 있어, 여드름을 치료하기 위한 다양한 방법에 관한 연구가 진행되고 있다.Recently, as interest in skin beauty has increased, the occurrence of acne has caused various psychological diseases such as psychological pressure, loss of self-confidence, and depression, and various studies for treating acne have been conducted .

종래에는, 상기한 여드름을 치료하기 위해서, 국소 치료, 광치료, 물리적 치료 또는 전신 치료 등의 다양한 방법을 이용하여 여드름을 치료하고 있으며, 특히, 국소치료는 피지 생성을 억제하는 항안드로겐제, 항염증제로 사용되는 비스테로이드소염제, 항균효과가 있는 레조시놀 또는 각종 항생제를 이용하여 수행되고 있으나, 상기 방법들은 여드름 치료 및 예방에는 효과가 있으나, 피부의 안정성을 해치는 등의 부작용을 초래할 수 있어, 이를 보완하기 위해, 부작용을 최소화할 수 있도록, 여드름을 치료하기 위해 천연물을 이용한 방법에 관한 연구가 지속되어 왔다.Conventionally, in order to treat the above-mentioned acne, acne is treated by various methods such as topical treatment, light treatment, physical treatment or systemic treatment. In particular, topical treatment is an anti-androgen agent for suppressing sebum production, Steroidal anti-inflammatory agents, resorcinols having antimicrobial effects, or various antibiotics. However, these methods are effective for the treatment and prevention of acne, but may cause adverse effects such as impairing the stability of the skin. In order to minimize side effects, research has been carried out on methods of using natural products to treat acne.

일례로, 종래 기술문헌 1에서는, 우엉 추출물, 버드나무 추출물, 녹차 추출물, 파파야 추출물, 키토산 및 피토스핑고신 등의 천연 항생물질을 포함하는 여드름 예방 또는 치료용 조성물에 관한 기술 내용을 개시한 바 있다.For example, the prior art document 1 discloses a technical content of a composition for preventing or treating acne including natural antibiotics such as burdock extract, willow extract, green tea extract, papaya extract, chitosan and phytosphingosine have.

또 다른 예로, 종래 기술문헌 2에서는, 아젤라인산(azelaic acid)를 유효성분으로 함유하는 여드름 치료용 조성물 및 이를 이용한 여드름 개선용 화장료 조성물에 관한 기술 내용을 개시한 바 있다.As another example, the prior art document 2 discloses a composition for treating acne containing azelaic acid as an active ingredient and a cosmetic composition for improving acne using the same.

하지만, 상기 문헌 1 및 2에 개시된 조성물 들은 단순히 여드름 치료의 목적으로만 용도가 국한되어 있어, 여드름 발병 후, 여드름에 의해 생성되는 흉터, 색소 침착 등의 효과적인 관리가 어렵고, 여드름이 발생된 피부 조직의 상처 치유 및 재생 능력 등이 떨어지며, 치료 가능한 여드름의 타입이 한정적인 특성을 보여 여드름 질환을 경험하고 있는 사람들에게 피부 미용을 개선하기 위한 용도로 사용하기에는 제한이 따른다는 문제가 있어, 이를 보완할 수 있는 방법에 대한 연구가 필요하다.However, since the compositions disclosed in the above documents 1 and 2 are limited only for the purpose of treating acne, it is difficult to effectively manage scars and pigmentation caused by acne after acne, The wound healing and regenerating ability of the skin is reduced, and the type of treatable acne is limited. Therefore, there is a problem in that people who experience acne disease have limitations in using it for improving skin beauty. There is a need for research on how to do this.

한국공개특허 제10-2010-0096394호 (공개일 : 2010.09.02)Korean Patent Publication No. 10-2010-0096394 (Disclosure Date: Sep. 2, 2010) 한국공개특허 제10-2011-0133198호 (공개일 : 2011.12.12)Korean Patent Laid-Open No. 10-2011-0133198 (published on December 12, 2011) 한국공개특허 제10-2013-0089045호 (공개일 : 2013.08.09)Korean Patent Publication No. 10-2013-0089045 (Publication date: 2013.08.09) 한국등록특허 제10-1427035호 (공개일 : 2014.08.05)Korean Patent No. 10-1427035 (Publication date: 2014.08.05)

본 발명은 상기한 바와 같은 종래기술의 문제점을 해결하기 위해 안출된 것으로, 상처 치유 및 재생 효능이 높아 여드름 치료에 효과적이면서도, 여드름에 의해 형성된 흉터, 색소 침착 등을 효과적으로 관리가능한 복합 기능을 갖는 여드름 치료 및 개선용 조성물에 관한 기술 내용을 제공하고자 하는 것이다.Disclosure of the Invention The present invention has been conceived to solve the problems of the prior art as described above, and it is an object of the present invention to provide an acne treatment method and an acne treatment method which can effectively manage acne, And to provide a technical content of the composition for treatment and improvement.

상기한 바와 같은 기술적 과제를 달성하기 위해서 본 발명은, 트라넥삼산(tranexamic acid, TXA), 피토스핑고신-1-포스페이트(phytosphingosine-1-phosphate) 및 미세조류 추출물을 포함하는 여드름 치료 및 개선용 조성물을 제공한다.In order to accomplish the above object, the present invention provides a method for treating and improving acne including tranexamic acid (TXA), phytosphingosine-1-phosphate and microalgae extract ≪ / RTI >

또한, 상기 트라넥삼산, 피토스핑고신-1-포스페이트 및 미세조류 추출물이 조성물의 총 중량대비 1 내지 20 중량%로 포함되는 것을 특징으로 한다.Also, the present invention is characterized in that the above-mentioned extracts of tranexamic acid, phytosphingosine-1-phosphate and microalgae are contained in an amount of 1 to 20% by weight based on the total weight of the composition.

또한, 상기 미세조류 추출물은 퓨칸 및 갈락탄을 포함하는 다당류; 및 오메가-3(omega-3), 오메가-6(omega-6), 디호모-감마리놀렌산(dihomo-gamma-linolenic acid), 에리코펜타엔산(eicosapentaenoic acid, EPA), 과산화벤조일(benzoyl peroxide) 및 살리실산(salicylic acid)으로 이루어진 군으로부터 선택되는 1종 이상을 포함하는 지방산을 포함하는 것을 특징으로 한다.Also, the microalgae extract may include polysaccharides including fucans and galactan; And omega-3, omega-6, dihomo-gamma-linolenic acid, eicosapentaenoic acid (EPA), benzoyl peroxide, And a fatty acid containing at least one member selected from the group consisting of salicylic acid.

또한, 상기 조성물은 화장수, 유액, 크림, 에센스, 화장연고, 스프레이, 젤, 팩, 선크림, 메이크업 베이스, 파운데이션, 파우더 및 세정제로 이루어진 군으로부터 선택되는 제형을 갖는 것을 특징으로 한다.In addition, the composition is characterized by having a formulation selected from the group consisting of lotion, milky lotion, cream, essence, cosmetic lotion, spray, gel, pack, sunscreen, makeup base, foundation, powder and detergent.

또한, 본 발명은 트라넥삼산, 피토스핑고신-1-포스페이트 및 미세조류 추출물을 유효성분으로 포함하는 여드름 치료 및 개선용 피부 외용제를 제공한다.In addition, the present invention provides an external preparation for skin for treating and improving acne, which comprises tranexamic acid, phytosphingosine-1-phosphate and microalgae extract as an active ingredient.

또한, 상기 외용제가 연고, 패치, 젤, 크림 및 분무제로 이루어진 군으로부터 선택되는 제형을 갖는 것을 특징으로 한다.Also, the external preparation is characterized in that it has a formulation selected from the group consisting of ointments, patches, gels, creams and sprays.

본 발명에 따른 여드름 치료 및 개선용 조성물은, 트라넥삼산, 피토스핑고신-1-포스페이트 및 미세조류 추출물을 유효성분으로 포함하여 여드름 치료 및 재생 효능이 높고, 여드름에 의해 형성된 흉터, 색소 침착 등을 효과적으로 관리할 수 있어 여드름 치료 및 개선에 관련한 의약외품 또는 코스메슈티컬 제품 제조에 효과적으로 응용이 가능하다.The composition for the treatment and improvement of acne according to the present invention is a composition for treating and improving acne, which comprises tranexamic acid, phytosphingosine-1-phosphate and microalgae extract as an active ingredient and has high acne treatment and regenerative effect, It can effectively be applied to quasi-drugs or cosmeceutical products related to the treatment and improvement of acne.

도 1은 실시예 및 비교예의 여드름 치료용 조성물의 조성을 나타낸 표이다.1 is a table showing compositions of acne treatment compositions of Examples and Comparative Examples.

이하, 본 발명을 상세히 설명하도록 한다.Hereinafter, the present invention will be described in detail.

본 발명은, 트라넥삼산(tranexamic acid, TXA), 피토스핑고신-1-포스페이트(phytosphingosine-1-phosphate) 및 미세조류 추출물을 유효성분으로 포함하는 여드름 치료 및 개선용 조성물을 제공한다.The present invention provides a composition for treating and improving acne comprising, as an active ingredient, tranexamic acid (TXA), phytosphingosine-1-phosphate and microalgae extract.

상기 트라넥삼산은 리신(lysine)에서 유래된 아미노산으로, 피부 장벽을 복구하고 손상된 피부를 회복시키는 기능이 있으며, 피부 상태를 좋게하고 수렴하는 효능이 있다. 또한, 활성화된 비만세포를 억제하는 플라스민 억제제로 작용해 멜라닌 색소가 넓게 퍼지는 것을 방지하는 기능을 하여 경계가 선명한 갈색 또는 흑갈색 기미인 간반 기미(chloasma)의 개선 효과가 우수하다.The above-mentioned tranexamic acid is an amino acid derived from lysine, has a function of restoring skin barrier and restoring damaged skin, and has an effect of improving and converging skin condition. In addition, it acts as a plasmin inhibitor that inhibits activated mast cells, thereby preventing the melanin pigment from spreading widely, and thus has an excellent effect of improving the chloasma, which has a clear brown or blackish brown hue.

하지만, 상기 트라넥삼산은 지혈제로 작용해 혈전이 생길수 있고, 혈액순환을 방해할 수 있으며, 결정성이 매우 높아 산소에 노출되면 결정이 쉽게 형성될 수 있는 문제가 있다. However, the above-mentioned tranexamic acid acts as a hemostatic agent, which can cause blood clots, interfere with blood circulation, and has a very high crystallinity, so crystals can easily be formed when exposed to oxygen.

상기 피토스핑고신-1-포스페이트는, 혈소판 풍부 혈청(platelet rich plasma, PRP)에서 다량 존재하는 트리메칠피토스핑고신의 유도체로서, 저농도에서도 사람의 진피세포(hypodermal cell)를 증식하는 효과가 우수해 피부에 도입시 탁월한 재생 효과를 기대할 수 있으며, 여드름의 발병에 의해 생성된 흉터 또는 여드름 제거후 생성되는 상처 부위를 효과적으로 치료할 수 있어 조성물에 포함될 수 있다.The above-mentioned phytosphingosine-1-phosphate is a derivative of trimethylphytosphingosine, which is abundantly present in platelet rich plasma (PRP), and has an effect of proliferating human hypodermal cells even at a low concentration It can be expected that an excellent regeneration effect can be expected when it is introduced into the skin and can be effectively included in the composition because scars generated by the onset of acne or wound areas generated after acne removal can be effectively treated.

상기 미세조류 추출물은 염증성 여드름 치료 및 개선 효과와 피부 노화 방지 및 피부 재생효과를 나타낼 수 있어, 여드름 치료 및 개선용 조성물에 포함될 수 있다. 상기 마세조류 추출물에는 다당류(polysaccharides) 및 지방산(fatty acids)이 포함되어 상기와 같은 효과를 기대할 수 있다.The microalgae extract can exhibit inflammatory acne treatment and improvement effect, prevention of skin aging and skin regeneration effect, and can be included in a composition for treating and improving acne. The above extracts of polysaccharides and fatty acids include polysaccharides and fatty acids.

보다 상세히 설명하면, 상기 미세조류 추출물은 다당류를 포함하여 염증성 여드름을 효과적으로 치료하여 우수한 피부 개선 효과를 갖는다. 상기 다당류는 퓨칸(fucan) 및 갈락탄(galactan)을 대표적인 예로 들 수 있다.In more detail, the microalgae extract contains a polysaccharide to effectively treat inflammatory acne and has an excellent skin improving effect. The polysaccharide may be exemplified by fucan and galactan.

상기 퓨칸은 항응고제(anticoagulant) 및 항혈전(antithrombotic activity) 효과가 우수해 피부를 이루는 각질세포가 자극되어 발생되는 염증 반응을 효과적으로 억제할 수 있고, 상기 트라넥삼산의 혈액응고작용을 예방할 수 있어, 여드름 치료 및 개선용 조성물에 포함될 수 있으며, 갈조류 유래 퓨쿠스속(fucus. sp)에서 추출한 퓨칸을 바람직하게 사용할 수 있다.The fucan is excellent in anticoagulant and antithrombotic activity and can effectively inhibit the inflammatory reaction caused by stimulation of keratinocytes forming the skin and prevent the blood coagulation action of the tranexamic acid, Can be included in a composition for treating and improving acne, and fucans extracted from fucus- derived fucus sp. Can be preferably used.

상기 갈락탄은 수분보유 능력이 탁월해 피부의 수분을 일정하게 유지할 수 있고, 이에 의해 상기 트라넥삼산의 결정형성을 방지하여 결정형성에 의한 피부 자극을 최소화할 수 있다. 또한, 이온성 물질의 농도를 일정하게 유지하는 pH 조절 기능이 있으며, 피부 삼투압 조절 등의 역할을 할 수 있을 뿐만 아니라, 항응고제 활성 및 항바이러스 활성, 항염증활성을 가져 여드름 치료 및 개선용 조성물에 포함될 수 있으며, 홍조류 유래 아스파라곱시스속(Asparagopsis. sp)에서 추출한 갈락탄을 바람직하게 사용할 수 있다. The galactan is excellent in water retention ability and can maintain the moisture of the skin constantly, thereby preventing crystal formation of the truncated triacid and minimizing skin irritation due to crystal formation. In addition, it has a pH control function that keeps the concentration of the ionic substance constant, and it can act as a skin osmotic pressure control, and has anticoagulant activity, antiviral activity, and anti-inflammatory activity, And galactan extracted from red algae derived asparagraphs ( Asparagopsis sp) can be preferably used.

또한, 상기 미세조류 추출물은 지방산을 포함하여 여드름 발병의 원인이되는 원인균에 대한 항균 활성을 나타내 여드름을 효과적으로 치료하여 우수한 피부 개선 효과를 나타내며, 상기 지방산은 오메가-3(omega-3), 오메가-6(omega-6), 디호모-감마리놀렌산(dihomo-gamma-linolenic acid), 에리코펜타엔산(eicosapentaenoic acid, EPA), 과산화벤조일(benzoyl peroxide) 및 살리실산(salicylic acid)를 포함할 수 있다.In addition, the microalgae extract has an antibacterial activity against causative bacteria that cause acne including fatty acids, and effectively treats acne, thereby exhibiting an excellent skin improving effect. The fatty acids are omega-3, omega- 6 omega-6, dihomo-gamma-linolenic acid, eicosapentaenoic acid (EPA), benzoyl peroxide, and salicylic acid.

본 발명에 따른 여드름 치료 및 개선용 조성물은 다양한 원인에 의해 발병되는 여드름을 효과적으로 개선 및 치료하기 위해서, 상기 트라넥삼산, 피토스핑고신-1-포스페이트 및 미세조류 추출물을 조성물의 총 중량대비 1 내지 20%로 포함하도록 구성할 수 있으며, 용도에 맞는 여드름 치료 및 개선용 조성물을 제조하기 위해, 각각의 성분의 함량을 조절할 수 있다.In order to effectively treat and treat acne caused by various causes, the composition for treating and improving acne according to the present invention is characterized in that the above-mentioned extracts of tranexamic acid, phytosphingosine-1-phosphate and microalgae To 20% by weight of the composition. In order to prepare a composition for treating and improving acne suitable for the application, the content of each component can be adjusted.

또한, 상기 트라넥삼산은, 0.01 내지 30 mg/g의 농도로 포함되도록 구성하여 트라넥삼산에 의한 효과를 극대화시킬 수 있다. 상기 트라넥삼산의 농도가 0.1 mg/g 이하로 포함될 경우, 트라넥삼산의 농도가 낮아 트라넥삼산에 의한 피부 재생 및 미백 효과를 기대하기 어려우며, 트라넥삼산의 농도가 300 mg/g을 초과하는 경우에는, 트라넥삼산의 피부 재생 및 미백 효과의 추가적인 증가가 더 이상 증가하지 않는다.In addition, the concentration of the above-mentioned tranexamic acid may be 0.01 to 30 mg / g to maximize the effect of the tranexamic acid. When the concentration of the tranexamic acid is less than 0.1 mg / g, it is difficult to expect skin regeneration and whitening effect due to the low concentration of tranexamic acid, and when the concentration of tranexamic acid exceeds 300 mg / g , The further increase in skin regeneration and whitening effect of tranexamic acid is no longer increased.

또한 상기 피토스핑고신-1-포스페이트는 0.001 내지 1 mg/g의 농도로 포함되도록 구성하여 피토스핑고신-1-포스페이트에 의한 효과를 극대화시킬 수 있다. 상기 상기 피토스핑고신-1-포스페이트의 농도가 0.001 mg/g 이하로 포함될 경우, 상기 피토스핑고신-1-포스페이트의 농도가 낮아 상기 피토스핑고신-1-포스페이트에 의한 피부 재생 및 미백 효과를 기대하기 어려우며, 상기 피토스핑고신-1-포스페이트의 농도가 1 mg/g을 초과하는 경우에는, 상기 피토스핑고신-1-포스페이트의 피부 재생 및 미백 효과의 추가적인 증가가 더 이상 증가하지 않는다.Also, the phytosphingosine-1-phosphate may be contained at a concentration of 0.001 to 1 mg / g to maximize the effect of phytosphingosine-1-phosphate. If the concentration of the phytosphingosine-1-phosphate is less than 0.001 mg / g, the concentration of the phytosphingosine-1-phosphate is low and the skin regeneration and whitening by the phytosphingosine- If the concentration of the phytosphingosine-1-phosphate exceeds 1 mg / g, the further increase in the skin regeneration and whitening effect of the phytosphingosine-1-phosphate is further increased I never do that.

또한, 상기 미세조류 추출물은 1 내지 20 중량%로 포함되도록 구성하여 미세조류 추출물에 의한 효과를 극대화시킬 수 있다. 상기 미세조류 추출물이 1 중량% 이하로 포함될 경우, 상기 미세조류 추출물의 농도가 낮아 상기 미세조류 추출물에 의한 치료효과를 기대하기 어려우며, 상기 미세조류 추출물이 20 중량%를 초과하여 포함될 경우에는, 상기 미세조류 추출물의 효과의 추가적인 증가가 더 이상 증가하지 않는다. In addition, the microalgae extract may be contained in an amount of 1 to 20% by weight to maximize the effect of the microalgae extract. When the microalgae extract is contained in an amount of less than 1% by weight, it is difficult to expect a therapeutic effect by the microalgae extract because the concentration of the microalgae extract is low. When the microalgae extract is contained in an amount of more than 20% No further increase in the effect of the microalgae extract is further increased.

본 발명에 따른 여드름 치료 및 개선용 조성물은 조성물 또는 조성물의 수화물 또는 용매화물 등의 형태로 단독으로 사용될 수 있고, 상기와 같은 제형으로 사용되기 위해, 사용방법 및 사용목적에 따라 약제학적으로 허용되거나 영양학적으로 허용되는 담체, 부형제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온 봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.The composition for treating and ameliorating acne according to the present invention may be used singly in the form of a hydrate or solvate of a composition or a composition, and may be pharmaceutically acceptable Nutritional acceptable carriers, excipients, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, May contain adjuvants conventionally used in the field of dermatology, such as topical agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredient commonly used in external preparations for skin.

또한, 본 발명에 따른 여드름 치료 및 개선용 조성물은, 수용성 고분자를 포함하는 하이드로겔의 형태로 제조가 가능하고, 수용성 고분자를 포함하여 유효성분을 충분히 담지하고 피부에 도입시 여드름의 치료 및 개선을 위해 지속적으로 유효성분을 방출할 수 있다.In addition, the composition for treating and improving acne according to the present invention can be prepared in the form of a hydrogel containing a water-soluble polymer, and it is also possible to provide an effective treatment of acne when the active ingredient is sufficiently contained, The active ingredient can be released continuously.

특히, 상기 수용성 고분자는 바이오 셀룰로오스, 젤라틴, β-락토글로불린, 유청, 콩 단백질, 감자 단백질, 잠두 단백질, 밀 단백질, 폴리-L-리신, 카제인염, 카제인, 콩 글리신, 소듐 알기네이트, 밀 전분, 옥수수 전분, 메틸 셀룰로오스, 에틸 셀룰로오스, 히드록시프로필 메틸 셀룰로오스, 셀룰로오스 나이트레이트, 카르복시메틸 셀룰로오스, 아라비아 고무, 크산탄 검, 메스키트 검, 구아 검, 카라기닌, 트라가칸트검, 아라비노갈락탄, 갈락토만난, 펙틴, 한천, 덱스트란, 키토산, 제인(zein), 히드록시프로필 메틸셀룰로오스 프탈레이트, 히드록시프로필 메틸셀룰로오스 아세테이트 숙시네이트, 폴리비닐 아세테이트 프탈레이트, 폴리(p-디옥사논), 폴리(β-발레로락톤), 폴리(β-히드록시부티레이트), 폴리(β-히드록시부티레이트) 및 β-히드록시발러레이트 공중합체, 폴리(β-히드록시프로피오네이트), 메틸아크릴산 공중합체, 디메틸아미노에틸 메타크릴레이트 공중합체, 트리메틸암모늄 에틸 메타크릴레이트 공중합체, 락트산 및 글리콜산의 중합체 및 공중합체, 락트산 및 글리콜산 및 폴리에틸렌 글리콜의 중합체 및 공중합체 또는 이들의 혼합물을 사용할 수 있으며, 바람직하게는 천연소재로 이루어진 바이오셀룰로오스 또는 발효 바이오셀룰로오스를 사용하도록 구성하여, 천연 소재의 우수한 밀착감과, 저자극의 특성을 동시에 가지는 하이드로겔 팩을 제조할 수 있다.Particularly, the water-soluble polymer may be at least one selected from the group consisting of bio-cellulose, gelatin,? -Lactoglobulin, whey, soy protein, potato protein, hazelnut protein, wheat protein, poly-L-lysine, casein, casein, soybean glycine, Corn starch, methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, cellulose nitrate, carboxymethyl cellulose, gum arabic, xanthan gum, mesquat gum, guar gum, carrageenin, tragacanth gum, arabinogalactan , Galactomannan, pectin, agar, dextran, chitosan, zein, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinylacetate phthalate, poly (p-dioxanone), poly (? -valerolactone), poly (? -hydroxybutyrate), poly (? -hydroxybutyrate) and? -hydroxy valerate Poly (? -Hydroxypropionate), methyl acrylate copolymer, dimethylaminoethyl methacrylate copolymer, trimethylammonium ethyl methacrylate copolymer, polymers and copolymers of lactic acid and glycolic acid, lactic acid and glycolic acid And polymers and copolymers of polyethylene glycol, or mixtures thereof. Preferably, a bio-cellulose or fermented bio-cellulose made of natural materials is used, so that a good adhesion property of natural materials and a low- A hydrogel pack can be prepared.

또는, 폴리아크릴산, 폴리아크릴산소다, 폴리아크릴아마이드, 폴리비닐알코올계, 폴리비닐피롤리돈계 또는 이들의 혼합물 등의 수용성 고분자를 사용할 수 있다.Alternatively, a water-soluble polymer such as polyacrylic acid, sodium polyacrylate, polyacrylamide, polyvinyl alcohol, polyvinyl pyrrolidone or a mixture thereof may be used.

상기한 바와 같은, 본 발명에 따른 여드름 치료 및 개선용 조성물은 화장수, 유액, 크림, 에센스, 화장연고, 스프레이, 젤, 팩, 선크림, 메이크업 베이스, 파운데이션, 파우더 또는 세정제 등의 제형으로 사용될 수 있다. As described above, the composition for treating and improving acne according to the present invention can be used in formulations such as lotion, milky lotion, cream, essence, cosmetic ointment, spray, gel, pack, sunscreen, makeup base, foundation, powder or detergent .

또한, 본 발명에 따른 여드름 치료 및 개선용 조성물은, 영양제, 비타민, 전해질, 풍미제, 착색제, 중진제, 펙트산, 알긴산, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 추가로 포함할 수 있다.The composition for treating and improving acne according to the present invention may further comprise at least one selected from the group consisting of a nutrient, a vitamin, an electrolyte, a flavoring agent, a colorant, a thickening agent, a pectic acid, an alginic acid, an organic acid, a protective colloid thickening agent, a pH adjusting agent, a stabilizer, Alcohols, carbonating agents used in carbonated drinks, and the like.

상기한 바와 같은 본 발명에 따른 여드름 치료 및 개선용 조성물은 트라넥삼산, 피토스핑고신-1-포스페이트 및 미세조류 추출물을 유효성분으로 포함하여 여드름 치료 및 재생 효능이 높고, 여드름에 의해 형성된 흉터, 색소 침착 등을 효과적으로 제거할 수 있어, 여드름 치료 및 개선에 관련한 의약외품 또는 코스메슈티컬(cosmeceutical) 제품 제조에 효과적으로 응용이 가능하다.As described above, the composition for treating and improving acne according to the present invention contains tranexamic acid, phytosphingosine-1-phosphate and microalgae extract as an active ingredient and has high therapeutic and regenerating effect against acne, , Pigmentation and the like can be effectively removed, and thus it can be effectively applied to the production of quasi-drugs or cosmeceutical products related to the treatment and improvement of acne.

또한, 본 발명은 트라넥삼산, 피토스핑고신-1-포스페이트 및 미세조류 추출물을 유효성분으로 포함하는 여드름 치료 및 개선용 피부 외용제를 제공한다.In addition, the present invention provides an external preparation for skin for treating and improving acne, which comprises tranexamic acid, phytosphingosine-1-phosphate and microalgae extract as an active ingredient.

상기 피부 외용제는 연고, 패치, 젤, 크림 또는 분무제 등의 제형으로 제조될 수 있고, 바세린, 스테아릴알콜 등의 기제, 폴리소르베이트, 솔르비탄 세스퀴올레이트 등의 계면활성제, 글리세린 등의 보습제, 착향제, 착색제, 안정화제, 점성화제, 약제학적으로 허용되는 용제 등을 균질하게 혼합하는 통상의 피부 외용제의 제조방법에 의해서 제조될 수 있다.The external preparation for skin may be formulated into ointments, patches, gels, creams, or spray formulations, and may be formulated with a base such as vaseline or stearyl alcohol, a surfactant such as polysorbate or sorbitan sesquioleate, a moisturizing agent such as glycerin, The present invention can be produced by a method for producing a conventional external preparation for skin, which comprises uniformly mixing a flavor, a colorant, a stabilizer, a tackifier, a pharmaceutically acceptable solvent, and the like.

이하, 본 발명을 실시예를 들어 더욱 상세히 설명하도록 한다.Hereinafter, the present invention will be described in more detail with reference to examples.

제시된 실시예는 본 발명의 구체적인 예시일 뿐이며, 본 발명의 범위를 제한하기 위한 것은 아니다.The embodiments presented are only a concrete example of the present invention and are not intended to limit the scope of the present invention.

<실시예><Examples>

홍조류 유래 아스파라곱시스속(Asparagopsis armata, KIOST) 미세 조류 및 갈조류 유래 퓨쿠스속(Fucus vesiculosus, KIOST) 미세 조류의 배양물에 아세톤 및 클로로포름을 9:4의 중량비로 포함하는 혼합용액과 1M의 질산을 순차적으로 첨가한 후, 10,000 rpm에서 10분 동안 원심분리하여 단백질 및 지질을 침전시키고, 상등액을 수득하였다. 수득한 상등액을 100,000 Mw 분자량을 배제하는 폴리설폰 나노여과막을 이용하여 상등액을 여과하여 홍조류 및 갈조류 유래 미세조류의 다당류를 분리하였다. 상등액을 HPLC로 분리하여 홍조류 유래 갈락탄을 분리 및 정제하였으며, 갈조류 유래 퓨칸을 분리 및 정제하였다. HPLC 컬럼은 5μ C18 컬럼(5μm, 4.6 × 250nm)을 사용하였다. 분석을 위한 용매는 0.1% 트리플루오로아세트산(TFA) 수용액(용매 A)와 아세토니트릴(용매B)을 사용하였고 1ml/분의 유속으로 300 내지 400 nm 파장에서 검출하였다.A mixed solution containing acetone and chloroform in a weight ratio of 9: 4 was added to a culture of microalgae ( Asparagopsis armata (KIOST) microalgae and brown algae derived fucus vesiculosus (KIOST) Nitric acid was added sequentially, followed by centrifugation at 10,000 rpm for 10 minutes to precipitate proteins and lipids, and supernatant was obtained. The resulting supernatant was filtered through a polysulfone nanofiltration membrane which excluded a molecular weight of 100,000 Mw and the supernatant was filtered to separate polysaccharides from microalgae derived from algae and brown algae. The supernatant was separated and purified by HPLC to separate and purify galactan from red algae, and the fucan derived from brown algae was separated and purified. The HPLC column used a 5 占 C18 column (5 占 퐉, 4.6 占 250 nm). The solvent for the analysis was a 0.1% trifluoroacetic acid (TFA) aqueous solution (solvent A) and acetonitrile (solvent B) and was detected at a wavelength of 300-400 nm at a flow rate of 1 ml / min.

또한, 오란티오키트리움속(Aurantiochytrium limacinum, KIOST) 미세조류 배양물을 이용하여 미세조류의 지방산을 분리하였다. 지방산의 분리는 동결건조한 배양물 분말을 초임계 추출 장치에 공급하고, 초임계 이산화탄소가 공급되는 조건에서 지방산을 추출하는 방법을 통해 미세조류에 포함된 지방산을 분리하여 지방산 분말을 수득하였다. In addition, microalgae fatty acids were isolated using a microalgae culture of the genus Aurantiochytrium limacinum (KIOST). Separation of fatty acids was performed by supplying the supernatant with a lyophilized culture powder and extracting the fatty acid under the condition of supercritical carbon dioxide to obtain a fatty acid powder by separating fatty acids contained in the microalgae.

상기와 같이 하여 수득한 미세조류 유래 퓨칸, 갈락탄 및 지방산을 트라넥삼산(LTBio, Product No. 4166) 및 피토스핑고신-1-포스페이트(BASF)를 포함하는 여드름 치료용 조성물을 제조하였으며, 제조한 조성물의 조성을 도 1에 나타내었다. The composition for treating acne including fungi, galactan and fatty acid derived from microalgae obtained as described above was prepared from LTBio (Product No. 4166) and Phytosphingosine-1-phosphate (BASF) The composition of the prepared composition is shown in Fig.

제조한 여드름 치료용 조성물을 폴리비닐알코올 및 폴리아크릴레이트계 수지를 포함하는 하이드로겔 조성물과 하기 표 1에 나타낸 바와 같은 조성으로 혼합하여 여드름 치료용 하이드로겔 연고를 제조하였다. 상기 하이드로겔 조성물을 혼합하여 제조하였다.The prepared acne treatment composition was mixed with a hydrogel composition containing polyvinyl alcohol and a polyacrylate resin in a composition as shown in Table 1 to prepare a hydrogel ointment for treating acne. The hydrogel composition was prepared by mixing.

Figure pat00001
Figure pat00001

<실험예 1> 미백 효과 확인<Experimental Example 1> Confirmation of whitening effect

(1) 멜라닌 세포 억제 능력 분석(1) Melanocyte inhibitory ability assay

실시예에 따른 방법에 의해 제조된 여드름 치료용 조성물을 최종 볼륨이 150g이 되도록 정제수와 혼합한 조성물 수용액을 제조하고, 조성물 수용액을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 첨가하여 2일 동안 배양하였다. 배양액을 교체한 후, 다시 2일 동안 배양한 세포 배양액에 트립신을 첨가한 후, 배양액을 원심분리하여 멜라닌을 추출하였으며, 추출한 멜라닌 혼합용액에 NaOH를 첨가하여 흡광도를 측정하고, 대조군과 비교하는 방법으로 하기 수학식 1을 사용하여 세포 수준에서 조성물 수용액의 미백 효과를 분석하였으며, 그 결과를 하기의 표 2에 나타내었다.An aqueous solution of the composition prepared by the method according to the Example was mixed with purified water so as to have a final volume of 150 g, and the aqueous solution of the composition was added to the culture solution of mouse melanoma cells (B-16 mouse melanoma cell) And cultured for 2 days. After replacing the culture medium, trypsin was added to the cell culture for another 2 days, and the melanin was extracted by centrifuging the culture. The absorbance was measured by adding NaOH to the mixed melanin solution and compared with the control , The whitening effect of the aqueous composition solution was analyzed at the cell level using the following equation (1). The results are shown in Table 2 below.

[수학식 1][Equation 1]

멜라닌 생성 억제율(%) = 100 X (시험물질의 흡광도 / 대조군의 흡광도)Melanin production inhibition rate (%) = 100 X (absorbance of test substance / absorbance of control group)

Figure pat00002
Figure pat00002

표 2에 나타난 바와 같이, 실시예 1-1 내지 실시예 1-4의 여드름 치료용 조성물로 처리한 시료에서는 트리넥삼산(TXA) 및 피토스핑고신-1-포스페이트(P-1-P)의 함량이 증가함에 따라, 멜라닌 생성 억제효과가 증가하는 것을 확인할 수 있었으며, 비교예 1의 여드름 치료용 조성물은 멜라닌 생성 억제효과가 미미하였고, 비교예 2의 여드름 치료용 조성물은 함량이 증가하여도 추가적인 멜라닌 생성 억제효과가 나타나지 않음을 확인할 수 있었다. (TXA) and phytosphingosine-1-phosphate (P-1-P) in the samples treated with the compositions for treating acne in Examples 1-1 to 1-4, It was confirmed that the melanin production inhibitory effect was increased with the increase of the content of the antioxidant, and the melanin production inhibitory effect of the composition for treating acne in Comparative Example 1 was insignificant, and the content of the composition for treating acne in Comparative Example 2 was increased It was confirmed that no additional melanin formation inhibitory effect was observed.

(2) 인체 피부 미백 효과 분석(2) Analysis of human skin whitening effect

실시예 2-1 내지 2-4의 하이드로겔 연고에 대한 인체 피부의 미백 효과를 검증하기 위해서, 건강한 남성 및 여성 20명을 대상으로 피검자의 양팔 하부에 직경 20 mm 크기의 구멍이 3개씩 3줄로 파인 알루미늄 호일을 붙이고, 팔에서 15 cm 떨어진 거리에서 인공광원기(solar simulator)를 사용하여 최소 홍반량(Minimal Erythma Dose)의 1.5 내지 2배 가량의 자외선 B(UV B)를 조사하여 피부 흑화를 유도하였다.To examine the whitening effect of the human skin on the hydrogel ointments of Examples 2-1 to 2-4, 20 healthy male and female subjects were divided into three rows each having three holes each having a diameter of 20 mm at the lower part of both arms of the subject Using a solar simulator at a distance of 15 cm from the arm, apply a fine aluminum foil and induce skin blackening by irradiating an ultraviolet B (UV B) of 1.5 to 2 times the Minimal Erythma Dose Respectively.

피부 흑화가 유도된 각각의 부위에 실시예 2-1 내지 2-4의 하이드로겔 연고를 1일 2회 도포하고, 45일 경과한 시점에서 색차계를 이용해 피부의 명암을 측정하였다. 하이드로겔 연고가 나타내는 미백 효과의 판정은 피부의 밝기정도(light value, L)를 구하여 결정하였다. L값의 측정은 색도계(Chromameter, 미놀타 CR-200)를 이용하여 측정하였다. 또한, 미백효과는 하기 수학식 2를 이용하여 하이드로겔 연고 도포전 시점과 도포 45일 경과한 시점에서의 피부 색도차(ΔL)로 미백효과를 판정하였으며, 그 결과를 하기의 표 3에 나타내었다.The hydrogel ointments of Examples 2-1 to 2-4 were applied twice a day to each site where skin blackening was induced. After 45 days, skin tone was measured using a colorimeter. The determination of the whitening effect exhibited by the hydrogel ointment was determined by determining the light value (L) of the skin. The L value was measured using a colorimeter (Chromameter, Minolta CR-200). In addition, the whitening effect was determined by the difference in skin chromaticity difference (? L) between the time before the application of the hydrogel ointment and the time after 45 days from the application using the following formula (2), and the results are shown in the following Table 3 .

[수학식 2]&Quot; (2) &quot;

ΔL = 도포 45일 경과한 시점의 L값 - 도포전 시점의 L값ΔL = L value at the end of 45 days of application - L value at the time of application

Figure pat00003
Figure pat00003

표 3에 나타낸 바와 같이, 비교예 3의 하이드로겔 연고는 미백 효과가 미미한 것을 확인할 수 있었고, 실시예 2-1 내지 2-4의 하이드로겔 연고는 미백효과가 증가하여 우수한 미백 효과를 나타냄을 확인할 수 있었다. 하지만, 비교예 4의 하이드로겔 연고에서 확인할 수 있는 바와 같이, 트리넥삼산 및 피토스핑고신-1-포스페이트의 함량이 증가하여도 미백효과가 더 이상 증가하지 않는 것을 확인할 수 있었다.As shown in Table 3, it was confirmed that the hydrogel ointment of Comparative Example 3 had a negligible whitening effect, and the hydrogel ointment of Examples 2-1 to 2-4 showed an excellent whitening effect by increasing the whitening effect I could. However, as can be seen from the hydrogel ointment of Comparative Example 4, it was confirmed that the whitening effect was not further increased even when the content of the trinectamic acid and the phytosphingosine-1-phosphate was increased.

또한, 제조한 하이드로겔 연고는 개봉후, 45일이 경과한 시점에서도 표면에 결정이 형성되지 않아 트라넥삼산을 안정하게 담지할 수 있는 것을 확인할 수 있었다.Further, it was confirmed that no crystals were formed on the surface even after 45 days from the opening of the hydrogel ointment so that the tranexamic acid can be stably carried.

<실험예 2> 여드름 질환 개선 효과 분석&Lt; Experimental Example 2 >

(1) 홍반 형성 억제 효과(1) Inhibitory effect on erythema formation

실험예 1과 동일한 조성물 수용이 갖는 여드름 질환 개선 효과를 분석하기 위해서, 프로피오니박테리움 아크네스(Propionibacterium acnes ATCC6919)에 의해 유도된 홍반에 대한 여드름 개선용 조성물 수용액의 효과를 생체내에서 확인하였다.In order to analyze the acne disease improving effect of the same composition as in Experimental Example 1, the effect of an aqueous solution of composition for improving acne against erythema induced by Propionibacterium acnes ATCC 6919 was confirmed in vivo.

5 X 108 CFU/ml 농도의 프로피오니박테리움 아크네스 균주 배양액 10 μl 및 실시예 1-3에 따른 여드름 개선용 조성물 수용액 20 μl의 혼합액을 마우스의 왼쪽 귀의 피하에 주사하고, 36시간 경과한 시점에서 마우스의 귀에 발생한 홍반을 현미경으로 관찰하였으며, 동일한 량의 프로피오니박테리움 아크네스 균주 배양액을 주사한 마우스를 대조군으로 하였다. A mixture of 10 μl of the culture broth of Propionibacterium acnes strain at a concentration of 5 × 10 8 CFU / ml and 20 μl of the aqueous solution of the composition for improving acne according to Example 1-3 was injected subcutaneously in the left ear of the mouse, and after 36 hours At the time point, erythema of the mouse ear was observed with a microscope, and a mouse injected with the same amount of the culture solution of Propionibacterium acnes strain was used as a control.

그 결과, 대조군의 마우스에 비해 실시예 1-3에 따른 여드름 개선용 조성물 수용액을 주사한 마우스에서 홍반의 생성률이 70% 이상 감소하였음을 육안으로 확인할 수 있었다.As a result, it was visually confirmed that the rate of erythema reduction in the mouse injected with the aqueous solution of the composition for improving acne according to Example 1-3 was reduced by 70% or more as compared with that of the mice of the control group.

(2) 여드름 원인균의 생장 억제 효과 확인(2) Confirming the growth inhibitory effect of acne causing bacteria

5 X 108 CFU/ml 농도의 프로피오니박테리움 아크네스 균주 배양액 10 μl 및 실시예 1-1 내지 1-4 및 비교예 1에 따른 여드름 개선용 조성물 수용액 20 μl의 혼합액을 BHI 배지(brain heart infusion buffer, 30g/L, BD, USA) 100ml과 혼합하여 혐기성 조건에서 배양하였으며, 여드름 개선용 조성물 수용액을 혼합하지 않은 균주 배양액 10 μl를 첨가하여 배양한 배양액을 대조군으로 하여 여드름 원인균의 증식 여부를 판별하였다.10 μl of the culture broth of Propionibacterium acnes strain at a concentration of 5 × 10 8 CFU / ml, and 20 μl of the aqueous solution of the composition for improving acne according to Examples 1-1 to 1-4 and Comparative Example 1 in a BHI medium The cultures were cultured under anaerobic conditions. The cultures were cultured in the presence of 10 μl of a culture medium containing no aqueous solution of acne improving composition as a control. Respectively.

그 결과, 대조군과 비교예 1에 따른 여드름 개선용 조성물 수용액으로 처리한 배지에서는 여드름 원인균이 증식되었음을 확인할 수 있었으나, 실시예 1-1 내지 1-4에 따른 여드름 개선용 조성물 수용액으로 처리한 배지에서는 여드름 원인균의 증식이 발생되지 않아, 여드름 개선용 조성물이 여드름 원인균의 생장을 효과적으로 억제한다는 사실을 확인할 수 있었다.As a result, it was confirmed that acne causative bacteria were proliferated in the medium treated with the control group and the aqueous solution of the composition for improving acne according to Comparative Example 1. However, in the medium treated with the aqueous solution of the composition for improving acne according to Examples 1-1 to 1-4 It was confirmed that the composition for improving acne effectively inhibited the growth of the causative agent of acne.

Claims (6)

트라넥삼산(tranexamic acid, TXA), 피토스핑고신-1-포스페이트(phytosphingosine-1-phosphate) 및 미세조류 추출물을 포함하는 여드름 치료 및 개선용 조성물.A composition for treating and improving acne comprising tranexamic acid (TXA), phytosphingosine-1-phosphate and microalgae extract. 제1항에 있어서,
상기 트라넥삼산, 피토스핑고신-1-포스페이트 및 미세조류 추출물이 조성물의 총 중량대비 1 내지 20 중량%로 포함되는 것을 특징으로 하는 조성물.
The method according to claim 1,
Wherein the extract of tranexamic acid, phytosphingosine-1-phosphate and microalgae is contained in an amount of 1 to 20% by weight based on the total weight of the composition.
제1항에 있어서,
상기 미세조류 추출물이 퓨칸 및 갈락탄을 포함하는 다당류; 및 오메가-3(omega-3), 오메가-6(omega-6), 디호모-감마리놀렌산(dihomo-gamma-linolenic acid), 에리코펜타엔산(eicosapentaenoic acid, EPA), 과산화벤조일(benzoyl peroxide) 및 살리실산(salicylic acid)으로 이루어진 군으로부터 선택되는 1종 이상을 포함하는 지방산을 포함하는 것을 특징으로 하는 조성물.
The method according to claim 1,
Wherein the microalgae extract comprises fucan and galactan; And omega-3, omega-6, dihomo-gamma-linolenic acid, eicosapentaenoic acid (EPA), benzoyl peroxide, And a fatty acid comprising at least one member selected from the group consisting of salicylic acid.
제1항에 있어서,
상기 조성물이 화장수, 유액, 크림, 에센스, 화장연고, 스프레이, 젤, 팩, 선크림, 메이크업 베이스, 파운데이션, 파우더 및 세정제로 이루어진 군으로부터 선택되는 제형을 갖는 것을 특징으로 하는 조성물.
The method according to claim 1,
Wherein the composition has a formulation selected from the group consisting of a lotion, an emulsion, a cream, an essence, a cosmetic ointment, a spray, a gel, a pack, a sunscreen, a makeup base, a foundation, a powder and a detergent.
트라넥삼산, 피토스핑고신-1-포스페이트 및 미세조류 추출물을 유효성분으로 포함하는 여드름 치료 및 개선용 피부 외용제.An external skin preparation for the treatment and improvement of acne comprising tranexamic acid, phytosphingosine-1-phosphate and microalgae extract as active ingredients. 제5항에 있어서,
상기 외용제가 연고, 패치, 젤, 크림 및 분무제로 이루어진 군으로부터 선택되는 제형을 갖는 것을 특징으로 하는 외용제.
6. The method of claim 5,
Wherein the external preparation has a formulation selected from the group consisting of ointments, patches, gels, creams and sprays.
KR1020160076415A 2016-06-20 2016-06-20 Composition of functional cosmetics and over the counter drugs for treating and improving acne KR101822154B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020160076415A KR101822154B1 (en) 2016-06-20 2016-06-20 Composition of functional cosmetics and over the counter drugs for treating and improving acne

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160076415A KR101822154B1 (en) 2016-06-20 2016-06-20 Composition of functional cosmetics and over the counter drugs for treating and improving acne

Publications (2)

Publication Number Publication Date
KR20170142632A true KR20170142632A (en) 2017-12-28
KR101822154B1 KR101822154B1 (en) 2018-01-26

Family

ID=60939772

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160076415A KR101822154B1 (en) 2016-06-20 2016-06-20 Composition of functional cosmetics and over the counter drugs for treating and improving acne

Country Status (1)

Country Link
KR (1) KR101822154B1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190089303A (en) * 2018-01-22 2019-07-31 주식회사 디알나노 Patch-type wound dressing comprising methylene blue mixture for treating skin wound
EP4045030A4 (en) * 2019-10-16 2024-03-13 Curology, Inc. Compositions and methods of treating acne and photoaging
FR3140547A1 (en) * 2022-10-07 2024-04-12 Laboratoires de Biologie Végétale Yves Rocher COSMETIC USE OF ASPARAGOPSIS EXTRACT FOR SEBUM REGULATING ACTION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3884581B2 (en) * 1998-10-05 2007-02-21 花王株式会社 Acne preventive / ameliorating agent
JP2015081244A (en) * 2013-10-23 2015-04-27 第一三共ヘルスケア株式会社 Acne treating pharmaceutical composition

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190089303A (en) * 2018-01-22 2019-07-31 주식회사 디알나노 Patch-type wound dressing comprising methylene blue mixture for treating skin wound
EP4045030A4 (en) * 2019-10-16 2024-03-13 Curology, Inc. Compositions and methods of treating acne and photoaging
FR3140547A1 (en) * 2022-10-07 2024-04-12 Laboratoires de Biologie Végétale Yves Rocher COSMETIC USE OF ASPARAGOPSIS EXTRACT FOR SEBUM REGULATING ACTION

Also Published As

Publication number Publication date
KR101822154B1 (en) 2018-01-26

Similar Documents

Publication Publication Date Title
JP2002193738A (en) Use of at least one extract from at least one azalea plant in composition for treating symptom of skin aging
KR101924956B1 (en) Composition for Improving Skin Wrinkle Comprising Mugunghwa Extract Treated by Enzyme as an Active Ingredient
EP0938891A1 (en) Cosmetic composition containing cinnamic acid or its derivatives and its use
KR101822154B1 (en) Composition of functional cosmetics and over the counter drugs for treating and improving acne
KR102499608B1 (en) Rejuvenating serum type cosmetic composition and manufacturing method thereof
JP2004512294A (en) Use of a combination of at least one carotenoid with provitamin A activity and at least one carotenoid without provitamin A activity for treating the signs of aging
KR102257448B1 (en) Cosmetic composition containing black kelp
KR102027647B1 (en) Low irritating cosmetic composition for skin whitening comprising albutin
JP6807636B2 (en) Topical composition
KR20090105222A (en) The cosmetic composition for the reduction of skin pores
JP4716497B2 (en) External preparation for skin and hyaluronidase inhibitor
JP3987733B2 (en) Fibroblast activator and skin external preparation containing the same
KR102107193B1 (en) Cosmetic composition comprising extract of calendula arvensis fermented by aureobasidium pullulans
JP2004359603A (en) Cell death inhibitor
KR102635022B1 (en) Cosmetic composition containing Perilla Ocymoides exosome, Eucalyptus Globulus exosome, elastic liposome containing azulene and peptides
KR20160000318A (en) Cosmetic composition containing Fir tree oil
KR101743001B1 (en) Cosmetic composition containing chitosan and propolis extracts
KR102517773B1 (en) Cosmetic composition containing potato flower ultrasonic extract as an active ingredient to have antioxidant and anti-inflammatory effects
KR102031663B1 (en) Cosmetic composition and external composition comprising glucosyl withanolides for anti-inflammatory
KR101993324B1 (en) Cosmetic Composition For Improvement of Skin Barrier
US20240000882A1 (en) Compositions and methods for body contouring and surgical procedures
KR102006872B1 (en) Cosmetic Composition Comprising Fermented Oil Extract of Oriental Medicine Fruits
JP2019069919A (en) Gelatinous composition
JP2002121110A (en) Cosmetic
WO2017188844A1 (en) Therapeutic cosmetic agent for the comprehensive treatment of dermatoses

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant